These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 24058629)
1. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. Scherpenisse M; Schepp RM; Mollers M; Meijer CJ; Berbers GA; van der Klis FR PLoS One; 2013; 8(9):e74797. PubMed ID: 24058629 [TBL] [Abstract][Full Text] [Related]
2. Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Dauner JG; Pan Y; Hildesheim A; Harro C; Pinto LA Vaccine; 2010 Jul; 28(33):5407-13. PubMed ID: 20591543 [TBL] [Abstract][Full Text] [Related]
3. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine. Godi A; Bissett SL; Miller E; Beddows S PLoS One; 2015; 10(10):e0140926. PubMed ID: 26495976 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay. Robbins HA; Waterboer T; Porras C; Kemp TJ; Pawlita M; Rodriguez AC; Wacholder S; Gonzalez P; Schiller JT; Lowy DR; Esser M; Matys K; Poncelet S; Herrero R; Hildesheim A; Pinto LA; Safaeian M Hum Vaccin Immunother; 2014; 10(10):2965-74. PubMed ID: 25483632 [TBL] [Abstract][Full Text] [Related]
5. Long-term HPV-specific immune response after one versus two and three doses of bivalent HPV vaccination in Dutch girls. Pasmans H; Schurink-Van't Klooster TM; Bogaard MJM; van Rooijen DM; de Melker HE; Welters MJP; van der Burg SH; van der Klis FRM; Buisman AM Vaccine; 2019 Nov; 37(49):7280-7288. PubMed ID: 31575492 [TBL] [Abstract][Full Text] [Related]
6. Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men. Pinto LA; Wilkin TJ; Kemp TJ; Abrahamsen M; Isaacs-Soriano K; Pan Y; Webster-Cyriaque J; Palefsky JM; Giuliano AR Vaccine; 2019 Apr; 37(18):2502-2510. PubMed ID: 30940485 [TBL] [Abstract][Full Text] [Related]
7. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial. Safaeian M; Kemp TJ; Pan DY; Porras C; Rodriguez AC; Schiffman M; Cortes B; Katki H; Wacholder S; Schiller JT; Gonzalez P; Penrose K; Lowy DR; Quint W; van Doorn LJ; Herrero R; Hildesheim A; Pinto LA Hum Vaccin Immunother; 2013 Jul; 9(7):1399-406. PubMed ID: 23571174 [TBL] [Abstract][Full Text] [Related]
8. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials. Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923 [TBL] [Abstract][Full Text] [Related]
9. Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix. Ferreira Costa AP; Gonçalves AK; Machado PRL; Souza LBFC; Sarmento A; Cobucci RNO; Giraldo PC; Witkin SS Asian Pac J Cancer Prev; 2018 Aug; 19(8):2313-2317. PubMed ID: 30141308 [TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids. Handisurya A; Schellenbacher C; Haitel A; Senger T; Kirnbauer R Br J Cancer; 2016 Feb; 114(4):409-16. PubMed ID: 26867163 [TBL] [Abstract][Full Text] [Related]
11. Persistence of immune response following bivalent HPV vaccination: A follow-up study among girls routinely vaccinated with a two-dose schedule. Schurink-van 't Klooster TM; Donken R; Schepp RM; van der Klis FRM; de Melker HE Vaccine; 2018 Nov; 36(49):7580-7587. PubMed ID: 30377068 [TBL] [Abstract][Full Text] [Related]
12. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls. Draper E; Bissett SL; Howell-Jones R; Waight P; Soldan K; Jit M; Andrews N; Miller E; Beddows S PLoS One; 2013; 8(5):e61825. PubMed ID: 23650505 [TBL] [Abstract][Full Text] [Related]
13. Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia. Mehta PA; Sauter S; Zhang X; Davies SM; Wells SI; Myers KC; Panicker G; Unger ER; Butsch Kovacic M Vaccine; 2017 Dec; 35(48 Pt B):6712-6719. PubMed ID: 29042204 [TBL] [Abstract][Full Text] [Related]
14. Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot study. Namujju PB; Pajunen E; Simen-Kapeu A; Hedman L; Merikukka M; Surcel HM; Kirnbauer R; Apter D; Paavonen J; Hedman K; Lehtinen M BMC Res Notes; 2014 Jul; 7():445. PubMed ID: 25011477 [TBL] [Abstract][Full Text] [Related]
15. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Kemp TJ; Hildesheim A; Safaeian M; Dauner JG; Pan Y; Porras C; Schiller JT; Lowy DR; Herrero R; Pinto LA Vaccine; 2011 Mar; 29(11):2011-4. PubMed ID: 21241731 [TBL] [Abstract][Full Text] [Related]
16. Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination. Scherpenisse M; Schepp RM; Mollers M; Mooij SH; Meijer CJ; Berbers GA; van der Klis FR Clin Vaccine Immunol; 2013 Aug; 20(8):1329-32. PubMed ID: 23740920 [TBL] [Abstract][Full Text] [Related]
17. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854 [TBL] [Abstract][Full Text] [Related]
18. Characterization of Immunoglobulin A/G Responses During 3 Doses of the Human Papillomavirus-16/18 ASO4-Adjuvanted Vaccine. Gonçalves AK; Giraldo PC; Farias KJ; Machado PR; Costa AP; de Souza LC; Crispim JC; Eleutério J; Witkin SS Sex Transm Dis; 2016 May; 43(5):335-9. PubMed ID: 27100772 [TBL] [Abstract][Full Text] [Related]
19. Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial. Pinto LA; Kemp TJ; Torres BN; Isaacs-Soriano K; Ingles D; Abrahamsen M; Pan Y; Lazcano-Ponce E; Salmeron J; Giuliano AR J Infect Dis; 2016 Oct; 214(8):1276-83. PubMed ID: 27511896 [TBL] [Abstract][Full Text] [Related]
20. First-void urine as a non-invasive liquid biopsy source to detect vaccine-induced human papillomavirus antibodies originating from cervicovaginal secretions. Van Keer S; Willhauck-Fleckenstein M; Pattyn J; Butt J; Tjalma WAA; Van Ostade X; Hens N; Van Damme P; Waterboer T; Vorsters A J Clin Virol; 2019 Aug; 117():11-18. PubMed ID: 31129514 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]